Alumis Inc. Sample Contracts
Shares ALUMIS INC. COMMON STOCK, PAR VALUE $0.0001 PER SHARE UNDERWRITING AGREEMENTUnderwriting Agreement • June 24th, 2024 • Alumis Inc. • Pharmaceutical preparations • New York
Alumis Inc., a Delaware corporation (the “Company”), proposes, subject to terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”), for whom Morgan Stanley & Co. LLC, Leerink Partners LLC, Cantor Fitzgerald & Co. and Guggenheim Securities, LLC are acting as representatives (the “Representatives”), [_________] shares of its common stock, par value $0.0001 per share (the “Firm Shares”). The Company also proposes to issue and sell to the several Underwriters not more than an additional [_________] shares of its common stock, par value $0.0001 per share (the “Additional Shares”), if and to the extent that the Representatives shall have determined to exercise, on behalf of the Underwriters, the right to purchase such shares of common stock granted to the Underwriters in Section 2 hereof. The Firm Shares and the Additional Shares are hereinafter collectively referred to as the “Shares.” The
Standard Contracts
ALUMIS INC. INDEMNIFICATION AGREEMENTIndemnification Agreement • June 24th, 2024 • Alumis Inc. • Pharmaceutical preparations • Delaware
This Indemnification Agreement (this “Agreement”) is dated as of __________, and is between Alumis Inc., a Delaware corporation (together with its subsidiaries, the “Company”), and __________ (“Indemnitee”).
January 12, 2022Employment Agreement • June 7th, 2024 • Alumis Inc. • Pharmaceutical preparations • California
We are pleased to present this offer of employment for the position of General Counsel of Alumis Inc. (the “Company”),. This is a full-time, exempt position, carrying considerable responsibility and is integral to the development and success of the business. We are excited about your interest in joining the Company full-time. This letter agreement formally presents the specifics of our offer for your consideration:
ContractOffer of Employment • June 7th, 2024 • Alumis Inc. • Pharmaceutical preparations
Certain information has been excluded from this agreement (indicated by “[***]”) because such information is both not material and the type that the registrant customarily and actually treats as private or confidential.
VOTING AND Support AGREEMENTVoting and Support Agreement • February 6th, 2025 • Alumis Inc. • Pharmaceutical preparations
This VOTING AND SUPPORT AGREEMENT (this “Agreement”) is made and entered into as of February 6, 2025, by and among Alumis Inc., a Delaware corporation (“Parent”), Arrow Merger Sub, Inc., a Delaware corporation and a direct wholly owned Subsidiary of Parent (“Merger Sub”) and the stockholder(s) of ACELYRIN, Inc., a Delaware corporation (the “Company”) listed on Schedule A hereto (each, a “Securityholder”). Capitalized terms used but not defined herein shall have the respective meanings ascribed to them in the Merger Agreement (as defined below).
ContractOffer of Employment • June 7th, 2024 • Alumis Inc. • Pharmaceutical preparations • California
Certain information has been excluded from this agreement (indicated by “[***]”) because such information is both not material and the type that the registrant customarily and actually treats as private or confidential.
AMENDMENT TO OFFER LETTEROffer Letter • June 7th, 2024 • Alumis Inc. • Pharmaceutical preparations • California
This Amendment to Offer Letter is made and entered into effective as of July 17, 2023 (the “Amendment Effective Date”), by and between Alumis Inc., a company organized under the laws of Delaware (the “Company”), and its Chief Development Officer Mark Bradley.
VOTING AND Support AGREEMENTVoting and Support Agreement • February 6th, 2025 • Alumis Inc. • Pharmaceutical preparations
This VOTING AND SUPPORT AGREEMENT (this “Agreement”) is made and entered into as of February 6, 2025, by and among ACELYRIN, Inc., a Delaware corporation (the “Company”), and the stockholder(s) of Alumis Inc., a Delaware corporation (“Parent”), listed on Schedule A hereto (each, a “Securityholder”). Capitalized terms used but not defined herein shall have the respective meanings ascribed to them in the Merger Agreement (as defined below).
AGREEMENT AND PLAN OF MERGER by and among ALUMIS INC., ARROW MERGER SUB, INC. and ACELYRIN, INC. Dated as of February 6, 2025Merger Agreement • February 6th, 2025 • Alumis Inc. • Pharmaceutical preparations • Delaware
This AGREEMENT AND PLAN OF MERGER (this “Agreement”), dated as of February 6, 2025, by and among Alumis Inc., a Delaware corporation (“Parent”), Arrow Merger Sub, Inc., a Delaware corporation and a direct wholly owned Subsidiary of Parent, (“Merger Sub”) and ACELYRIN, Inc., a Delaware corporation (the “Company”). Parent, Merger Sub and the Company are each sometimes referred to herein as a “Party” and collectively as the “Parties”.
STOCK PURCHASE AGREEMENT dated as of March 5, 2021 by and among FL2021-001, INC., AS PURCHASER, FRONTHERA INTERNATIONAL GROUP LIMITED, AS SELLER AND FRONTHERA U.S. HOLDINGS, INC., AS THE COMPANYStock Purchase Agreement • June 7th, 2024 • Alumis Inc. • Pharmaceutical preparations • Delaware
THIS STOCK PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of March 5, 2021 by and among (i) FL2021-001, Inc., a Delaware corporation (“Purchaser”); (ii) FronThera International Group Limited, an exempted company incorporated in the Cayman Islands with limited liability (“Seller”); and (iii) FronThera U.S. Holdings, Inc., a Delaware corporation (the “Company”). Purchaser, Seller and the Company will be individually referred to herein as a “Party” and collectively referred to herein as the “Parties”.
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • June 7th, 2024 • Alumis Inc. • Pharmaceutical preparations • Delaware
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 4th day of March, 2024 by and among Alumis Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”.
COMMON STOCK PURCHASE AGREEMENTCommon Stock Purchase Agreement • July 3rd, 2024 • Alumis Inc. • Pharmaceutical preparations • New York
This COMMON STOCK PURCHASE AGREEMENT (this “Agreement”) is made as of June 27, 2024 (the “Effective Date”), by and among Alumis Inc., a Delaware corporation (the “Company”), and AyurMaya Capital Management Fund, LP (the “Investor”).
LEASE AGREEMENTLease Agreement • May 15th, 2024 • Alumis Inc. • Pharmaceutical preparations
THIS LEASE AGREEMENT (this “Lease”) is made this ____ day of July, 2021, between 611 GATEWAY CENTER LP, a Delaware limited partnership (“Landlord”), and ESKER THERAPEUTICS, INC., a Delaware corporation (“Tenant”).
SUMMARY OF BASIC LEASE INFORMATIONLease • June 7th, 2024 • Alumis Inc. • Pharmaceutical preparations • California
